1887
  1. Home
  2. Eurosurveillance
  3. Volume 28, Issue 7, 16/Feb/2023
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18–59-year-olds and 14% in 60–85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2023.28.7.2300087
2023-02-16
2024-04-19
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2023.28.7.2300087
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/28/7/eurosurv-28-7-1.html?itemId=/content/10.2807/1560-7917.ES.2023.28.7.2300087&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). One year since the emergence of COVID-19 virus variant Omicron. Geneva: WHO; 2022. Available from: https://www.who.int/news-room/feature-stories/detail/one-year-since-the-emergence-of-omicron
  2. European Medicines Agency (EMA). First adapted COVID-19 booster vaccines recommended for approval in the EU. EMA; 2022. Available from: https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-recommended-approval-eu
  3. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). Varianten van het coronavirus SARS-CoV-2.[Variants of the coronavirus SARS-CoV-2]. Bilthoven: RIVM; 2023. Dutch. Available from: https://www.rivm.nl/coronavirus-covid-19/virus/varianten
  4. Huiberts A, Kooijman M, de Melker H, Hahne S, Grobbee D, Hoeve C, et al. Design and baseline description of an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands - The VAccine Study COvid-19 (VASCO)[PREPRINT]. Research Square. 2022 https://doi.org/10.21203/rs.3.rs-1645696/v1 
  5. Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahné SJM, Hartog Gd, et al. Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from 12 July 2021 to 6 June 2022: a prospective cohort study [PREPRINT]. medRxiv. 2023:2023.01.09.23284335.  https://doi.org/10.1101/2023.01.09.23284335  https://doi.org/10.1101/2023.01.09.23284335 
  6. Rijksoverheid. Coronadashboard: Virusdeeltjes in rioolwater. [Coronavirus dashboard. Virus particles in wastewater]. Den Haag: Rijksoverheid. [Accessed: 17 Jan 2023]. Dutch. Available from: https://coronadashboard.government.nl/landelijk/rioolwater
  7. Rijksoverheid. Coronadashboard: Positief geteste mensen. [Coronavirus dashboard. Positive tests]. Den Haag: Rijksoverheid. [Accessed: 17 Jan 2023]. Dutch. Available from: https://coronadashboard.rijksoverheid.nl/landelijk/positief-geteste-mensen
  8. Link-Gelles R, Ciesla AA, Fleming-Dutra KE, Smith ZR, Britton A, Wiegand RE, et al. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1526-30.  https://doi.org/10.15585/mmwr.mm7148e1  PMID: 36454688 
  9. Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al. Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the Nordic countries[PREPRINT]. medRxiv. 2023:2023.01.19.23284764 https://doi.org/10.1101/2023.01.19.23284764 
  10. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). RIVM COVID-19 epidemiologie en surveillance team. COVID-19 ziekenhuis en intensive-care-opnames per vaccinatiestatus in Nederland (opnames 3 oktober 2022 – 9 januari 2022). [COVID-19 hospital and intensive care admissions by vaccination status in the Netherlands (admissions 3 October 2022 – 9 January 2023)]. Bilthoven: RIVM; 2023. Dutch. Available from: https://www.rivm.nl/documenten/covid-19-ziekenhuis-en-intensive-care-opnames-per-vaccinatiestatus-in-nederland-5
  11. Wei J, Matthews PC, Stoesser N, Newton JN, Diamond I, Studley R, et al. Correlates of protection against SARS-CoV-2 Omicron variant and anti-spike antibody responses after a third/booster vaccination or breakthrough infection in the UK general population [PREPRINT]. medRxiv. 2022:2022.11.29.22282916 https://doi.org/10.1101/2022.11.29.22282916 
  12. Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023;S1473-3099(22)00801-5.  https://doi.org/10.1016/S1473-3099(22)00801-5  PMID: 36681084 
  13. de Gier B, Huiberts AJ, Hoeve CE, Hartog Gd, van Werkhoven H, van Binnendijk R, et al. The effect of previous SARS-CoV-2 infection and COVID-19 vaccination on SARS-CoV-2 Omicron infection and relation with serological response – a prospective cohort study [PREPRINT]. medRxiv. 2023:2023.01.09.23284334  https://doi.org/10.1101/2023.01.09.23284334  https://doi.org/10.1101/2023.01.09.23284334 
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Anne+J+Huiberts&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Huiberts Anne J</a>, <a href="/search?value1=Brechje+de+Gier&option1=author&noRedirect=true" class="nonDisambigAuthorLink">de Gier Brechje</a>, <a href="/search?value1=Christina+E+Hoeve&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hoeve Christina E</a>, <a href="/search?value1=Hester+E+de+Melker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">de Melker Hester E</a>, <a href="/search?value1=Susan+JM+Hahn%C3%A9&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hahné Susan JM</a>, <a href="/search?value1=Gerco+den+Hartog&option1=author&noRedirect=true" class="nonDisambigAuthorLink">den Hartog Gerco</a>, <a href="/search?value1=Janneke+HHM+van+de+Wijgert&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van de Wijgert Janneke HHM</a>, <a href="/search?value1=Susan+van+den+Hof&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van den Hof Susan</a>, <a href="/search?value1=Mirjam+J+Knol&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Knol Mirjam J</a></span>. Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022. <a href="/content/ecdc">Euro Surveill.</a> 2023;28(7):pii=2300087. <a href="https://doi.org/10.2807/1560-7917.ES.2023.28.7.2300087" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2023.28.7.2300087</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 02 Feb 2022;&nbsp;&nbsp; <span class="generated">Accepted</span>: 16 Feb 2023 </span> </p>
/content/10.2807/1560-7917.ES.2023.28.7.2300087
/content/10.2807/1560-7917.ES.2023.28.7.2300087
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error